COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Funding Opportunities & Translational Resources

The National Cancer Institute’s Nanodelivery Systems and Devices Branch has compiled the following list of funding opportunities and translational resources that may be of interest to nanotech developers. Click the link for each announcement to learn more.

Nanotechnology-Focused:

  • PAR 20-284 – Innovative Research in Cancer Nanotechnology (R01 Clinical Trials Not Allowed).  The proposal should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. Receipt dates: November 4, 2020, May 6, 2021, November 4, 2021, May 5, 2022, November 3, 2022, May 4, 2023
  • PAR 20-116 – Toward Translation of Nanotechnology Cancer Interventions (R01 Clinical Trials Not Allowed).  The award is designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs. Receipt dates: November 19, 2020, May 20, 2021, November 18, 2021

 

Clinical/Translational Programs and Funding Opportunities:

  • PAR-18-560: Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required).  The FOA supports research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of NCI’s Division of Cancer Treatment and Diagnosis (DCTD).  Due Standard Dates through Jan 8, 2021.
  • NCI Experimental Therapeutics Program (NExT): Please note that the NExT Program is not a grant mechanism; applications with exceptional science cannot be accepted without a clear path to the clinic or potential benefit to patients. The mission of the NExT Program is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects. Awardees will not necessarily receive direct funding; rather, the NCI may allocate various contract and grant resources toward the implementation and development of submitted projects. The NCI will partner with successful applicants to facilitate the milestone-driven progression of new anticancer drugs (small molecules, biologics) and imaging agents towards clinical evaluation and registration.  See application instructions.

 

Basic/Applied Science Programs and Funding Opportunities:

 

Team Science Funding Opportunities